What we do

Mass in vivo analysis

What we do

Mass in vivo analysis

Personal Discovery ProcessTM
replicates a patient’s genetic profile and screens thousands of drug cocktails

icon
 

01  Patient’s entire exome analysed to capture tumour network

 

 

 

02  Mutations comprising patient’s tumour network engineered into fruit fly avatar

 

Fly
Fly
 

03  All FDA approved drugs screened – up to half a million avatars

 

 

04  Treatment recommendations report – generally for combination therapy

 

Fly
The Personal Discovery Process (PDP) provides individuals with treatment-driven research on an unprecedented scale. It is effectively a massive clinical trial for a single patient. We engineer the genetic complexity of each patient’s unique tumour network into an army of 500,000 fruit fly “avatars”. Using robotics, we evaluate up to 2,000 FDA approved drugs including non-cancer drugs, to identify drug combinations that are efficacious in the individual’s avatar population.

The Icahn School of Medicine at Mount Sinai developed the PDP methodology over years of clinical research. They found that real-world patient tumours are made resistant to single-drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The Personal Discovery Process methods are licensed exclusively to My Personal Therapeutics (trading as Vivan Therapeutics).

Logo Perlara
Logo Genomics England
Logo Mount Sinai
Logo NIHR
 

Our Partners

 

Backed by

Logo Mount Sinai
Logo NIHR
Logo Perlara
Logo Genomics England
 

Media and Press

Logo Genome Web
Logo New Scientist
Logo Forbes

Where to meet us next

A
Advanced Therapies Live 2022
May 23-25 2022. Click for more details
A
Oncology Strategy Meeting Europe 2022

Order now or contact us to learn more